Neumora Therapeutics, Inc. (NMRA) · Oct 30, 2026 · Delisting

Neumora delisting warning puts Nasdaq listing at risk

Bid-price deficiency — $1.00 minimum bid; 180 days to April 26, 2027

Neumora’s delisting notice gives the biotech 180 days to regain Nasdaq’s $1 minimum bid price, adding a capital-markets problem to its pipeline rebuild.

Neumora is a clinical-stage biotech rebuilding around newer programs including NMRA-511, NMRA-898, and NMRA-215 after its late-stage navacaprant depression studies failed; management’s latest plan still pointed to clinical data and new program advancement in late 2026. This filing does not change that pipeline, but it adds a new exchange-compliance problem to the story.

The listing is now formally at risk, not immediately lost. Nasdaq says Neumora is below the $1.00 minimum bid requirement, giving it until April 26, 2027 to post a closing bid of at least $1.00 for ten consecutive business days.

The likely remedy could create a corporate-action overhang. Neumora says it is considering options including a reverse stock split, while a failure to cure the deficiency could lead to delisting proceedings and a possible appeal. 〔0〕 A reverse split would mechanically raise the quoted share price but would not improve the underlying pipeline, financing capacity, or clinical evidence.

This is partly known but still negative new information. A prolonged sub-$1 share price made a deficiency notice foreseeable, so the filing is not a surprise about the company’s operating science. But the formal deadline and explicit reverse-split consideration convert that weakness into a defined capital-markets issue while investors await the next clinical milestones.

Bottom line: Neumora has time to cure the Nasdaq deficiency, but the filing adds avoidable listing and reverse-split risk to an already high-stakes pipeline rebuild. It matters more for the company’s financing and market-access mechanics than for its drug programs themselves.

What to watch next

Regain $1 bid price by April 26, 2027

Original filing on SEC EDGAR

Neumora delisting warning puts Nasdaq listing at risk | NMRA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.